Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0053 | 1 | 0.5 |
Trypanosoma brucei | protein kinase, putative | 0.0053 | 1 | 0.5 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0051 | 0.9346 | 0.9346 |
Leishmania major | mitogen activated protein kinase, putative,map kinase, putative | 0.0053 | 1 | 0.5 |
Toxoplasma gondii | CMGC kinase, MAPK family (ERK) MAPK-1 | 0.0053 | 1 | 0.5 |
Echinococcus granulosus | mitogen activated protein kinase 3 | 0.0053 | 1 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase 3 | 0.0053 | 1 | 0.5 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0051 | 0.9346 | 0.9346 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0053 | 1 | 1 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0053 | 1 | 0.5 |
Trypanosoma cruzi | mitogen activated protein kinase 4, putative | 0.0053 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0051 | 0.9346 | 0.9346 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0053 | 1 | 0.5 |
Trypanosoma cruzi | mitogen activated protein kinase 2, putative | 0.0053 | 1 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase | 0.0053 | 1 | 0.5 |
Trypanosoma brucei | mitogen activated protein kinase 4, putative | 0.0053 | 1 | 0.5 |
Loa Loa (eye worm) | CMGC/MAPK/ERK1 protein kinase | 0.0053 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0053 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0053 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0053 | 1 | 0.5 |
Leishmania major | mitogen activated protein kinase 4, putative;with=GeneDB:LmxM19.1440 | 0.0053 | 1 | 0.5 |
Giardia lamblia | Kinase, CMGC MAPK | 0.0053 | 1 | 0.5 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0051 | 0.9346 | 0.9346 |
Echinococcus granulosus | mitogen activated protein kinase | 0.0053 | 1 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.